Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study to determine the safety and efficacy of IMN-003A cell therapy in patients with relapsed and refractory CD19 positive B cell malignancies

Next Previous
Trial Profile

A phase 2 study to determine the safety and efficacy of IMN-003A cell therapy in patients with relapsed and refractory CD19 positive B cell malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varnimcabtagene-Autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMAGINE
  • Sponsors Immuneel Therapeutics

Most Recent Events

  • 12 Dec 2023 According to a results presented at the 65th American Society of Hematology Annual Meeting and Exposition, updated results will be presented in the meeting.
  • 12 Dec 2023 Primary analysis (At data cut-off; n= 25) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 15 Jun 2023 Results (n=21) assessing pharmacokinetic data and correlation with disease response presented at the 28th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top